home / stock / agle / agle news

AGLE News and Press, Aeglea BioTherapeutics Inc. From 02/28/19

Stock Information
Company Name: Aeglea BioTherapeutics Inc.
Stock Symbol: AGLE
Market: NASDAQ
Website: aegleabio.com
Menu
AGLE AGLE Quote AGLE Short AGLE News AGLE Articles AGLE Message Board
Get AGLE Alerts

News, Short Squeeze, Breakout and More Instantly...
AGLE - Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call

AUSTIN, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth qua...
AGLE - Healthcare and Tech tops midday movers

Gainers:  MacroGenics (NASDAQ: MGNX ) +129% . Snap (NYSE: SNAP ) +24% . Jason Industries (NASDAQ: JASN ) +23% . Bionano Genomics (NASDAQ: BNGO ) +16% . Proteostasis Therapeutics (NASDAQ: PTI ) +16% . Plantronics (NYSE: PLT ) +15% . Neon Therapeutics (NASDAQ: NTGN ) +15% . MaxLi...

AGLE - ATVI, EA among premarket losers

Arlo Technologies (NYSE: ARLO )  -31%  on Q4 earnings . More news on: Arlo Technologies, CCA Industries Inc, Catabasis Pharmaceuticals, Stocks on the move, Read more ...

AGLE - Aeglea Biotherapeutics prices $60M equity offering

Aeglea BioTherapeutics (NASDAQ: AGLE ) has priced public offering of 3.75M common stock at $8.00 per share, for expected gross proceeds of ~$60M. More news on: Aeglea BioTherapeutics, Healthcare stocks news, Read more ...

AGLE - Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering

AUSTIN, Texas, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of an underwritt...

AGLE - Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it intends to offer and...

Previous 10 Next 10